| 0 (0%) | 12-05 09:28 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 46.02 | 1-year : | 47.17 |
| Resists | First : | 39.4 | Second : | 40.38 |
| Pivot price | 39.44 |
|||
| Supports | First : | 37.81 | Second : | 31.45 |
| MAs | MA(5) : | 38.87 |
MA(20) : | 39.44 |
| MA(100) : | 38.66  |
MA(250) : | 0 | |
| MACD | MACD : | -0.2 |
Signal : | 0 |
| %K %D | K(14,3) : | 11.7 |
D(3) : | 13.9 |
| RSI | RSI(14): 39.9 |
|||
| 52-week | High : | 40.5 | Low : | 30.59 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ CNP ] has closed above bottom band by 10.2%. Bollinger Bands are 23% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 38.9 - 39.05 | 39.05 - 39.22 |
| Low: | 37.88 - 38.04 | 38.04 - 38.23 |
| Close: | 38.24 - 38.5 | 38.5 - 38.8 |
Thu, 04 Dec 2025
Palantir Stock Rises -- Teams Up with Nvidia to Accelerate AI Infrastructure - TradingView
Thu, 04 Dec 2025
Schroder Investment Management Group Grows Stock Holdings in CenterPoint Energy, Inc. $CNP - MarketBeat
Wed, 03 Dec 2025
CenterPoint Energy: A Particularly Well-Positioned Utility (NYSE:CNP) - Seeking Alpha
Mon, 01 Dec 2025
FDA Delays Decision on Ascendis’ Dwarfism Drug by Three Months - BioSpace
Fri, 28 Nov 2025
How the FDA’s TransCon CNP Review Delay at Ascendis Pharma (ASND) Has Changed Its Investment Story - Yahoo Finance
Wed, 26 Nov 2025
FDA delays decision on Ascendis' dwarfism prospect by 3 months - Fierce Biotech
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 653 (M) |
| Shares Float | 649 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 101.1 (%) |
| Shares Short | 31,240 (K) |
| Shares Short P.Month | 33,770 (K) |
| EPS | 1.58 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 16.89 |
| Profit Margin | 11.3 % |
| Operating Margin | 24.9 % |
| Return on Assets (ttm) | 2.9 % |
| Return on Equity (ttm) | 9.6 % |
| Qtrly Rev. Growth | 7 % |
| Gross Profit (p.s.) | 6.29 |
| Sales Per Share | 13.95 |
| EBITDA (p.s.) | 5.25 |
| Qtrly Earnings Growth | 50.5 % |
| Operating Cash Flow | 2,600 (M) |
| Levered Free Cash Flow | -3,120 (M) |
| PE Ratio | 24.39 |
| PEG Ratio | 0 |
| Price to Book value | 2.28 |
| Price to Sales | 2.76 |
| Price to Cash Flow | 9.67 |
| Dividend | 0.21 |
| Forward Dividend | 0 |
| Dividend Yield | 0.5% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|